Major Depression Disorder (MDD)
Conditions
Brief summary
• Time-to-relapse after induction phase assessed by clinician rated MADRS between all 3 treatment arms, • Time-to-relapse after the last ketamine infusion assessed by clinician rated MADRS between all three treatment arms
Detailed description
• Assess frequency, severity and duration of ARs/SARs through clinical interview, observation, SCI-2 SF, DLCQ and PreKET symptom checklist, patient chart review, spontaneously reported adverse events from signing the ICF to Final visit.
Interventions
DRUGKETAMINE HYDROCHLORIDE
Sponsors
Ostfold Hospital Trust
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Time-to-relapse after induction phase assessed by clinician rated MADRS between all 3 treatment arms, • Time-to-relapse after the last ketamine infusion assessed by clinician rated MADRS between all three treatment arms | — |
Secondary
| Measure | Time frame |
|---|---|
| • Assess frequency, severity and duration of ARs/SARs through clinical interview, observation, SCI-2 SF, DLCQ and PreKET symptom checklist, patient chart review, spontaneously reported adverse events from signing the ICF to Final visit. | — |
Countries
Norway
Outcome results
None listed